Skip to main content
Fig. 5 | Journal of Translational Medicine

Fig. 5

From: Potential benefit of osimertinib plus bevacizumab in leptomeningeal metastasis with EGFR mutant non-small-cell lung cancer

Fig. 5

Osimertinib plus bevacizumab modulates E-cadherin levels in EGFR-mutant LM model mice. A E-cadherin were assessed in the tumor tissues by WB. B grayscale value of E-cadherin (a), quantification of PCNA (b) and E-cadherin (c) by IHC (d). C PCNA, E-cadherin were assessed in the tumor tissues by IHC. (n = 3, *means p < 0.05, **means p < 0.01, *** means p < 0.001, **** means p < 0.0001, one-way ANOVA)

Back to article page